October 2013. All four DENV NS1 serotypes have been manufactured in response to the unmet need for highly purified, concentrated proteins for use in vaccine development and serological based diagnostic assays.
To achieve this, the company has employed its novel VirTuETM platform which is based entirely on human cell lines using state-of-the-art expression techniques. Dr Holger Hannemann, Lead Scientist at The Native Antigen Company said: “Our aim was to focus on NS1’s native hexameric presentation. The hexamer is believed to be the biologically active form of NS1 involved in key aspects of dengue pathogenesis. The resultant DENV NS1 proteins are purified to a high degree, are in their native folding state, and possess all post-translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin.”
With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics. As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus.
For more information please contact The Native Antigen Company on +44 (0)1869 238067, contact@thenativeantigencompany.com or visit www.thenativeantigencompany.com
Help employers find you! Check out all the jobs and post your resume.
